Hematology Oncology · Year 2 · from Hematology Oncology
Case 1: Multiple Myeloma with CRAB Features
Patient Presentation
Demographics: 68-year-old male
Chief Complaint: Back pain and fatigue for 3 months
History of Present Illness: The patient has had progressive lower back pain for 3 months that does not improve with rest. He also reports significant fatigue, decreased appetite, and constipation. He was recently found to have elevated creatinine on routine labs. He denies fever, weight loss, or night sweats.
Past Medical History:
- Hypertension
- Type 2 diabetes mellitus
Physical Examination:
- Blood pressure: 132/78 mmHg
- Heart rate: 84 bpm
- General: Pale, appears fatigued
- Spine: Tenderness to palpation at L2-L4
- No hepatosplenomegaly
- No lymphadenopathy
- No focal neurological deficits
Workup and Results
Laboratory Studies:
- Hemoglobin: 9.2 g/dL
- Creatinine: 2.4 mg/dL (baseline 1.0)
- Calcium: 12.8 mg/dL (elevated)
- Albumin: 3.2 g/dL
- Total protein: 10.4 g/dL (elevated)
- Beta-2 microglobulin: 6.8 mg/L (elevated)
- LDH: 245 U/L (upper normal)
Serum Protein Electrophoresis (SPEP):
- M-spike: 4.2 g/dL (IgG kappa)
Serum Free Light Chains:
- Kappa: 285 mg/L (elevated)
- Lambda: 12 mg/L
- Ratio: 23.75 (abnormal)
Skeletal Survey:
- Multiple lytic "punched-out" lesions in skull, spine, and pelvis
- L3 compression fracture
Bone Marrow Biopsy:
- 65% clonal plasma cells
- CD138+, cytoplasmic kappa light chain restricted
- Cytogenetics: Standard risk
Clinical Image
Skull X-ray demonstrating multiple "punched-out" lytic lesions characteristic of multiple myeloma. Bone scans are often negative because there is no osteoblastic activity.
Diagnosis
Multiple Myeloma - IgG Kappa, ISS Stage III
CRAB criteria present:
- Calcium elevation (12.8 mg/dL)
- Renal insufficiency (creatinine 2.4 mg/dL)
- Anemia (hemoglobin 9.2 g/dL)
- Bone lesions (lytic lesions with compression fracture)
R-ISS Staging: Stage III (beta-2 microglobulin >5.5 mg/L)
Discussion
This case illustrates classic multiple myeloma:
- CRAB Criteria: The lecture describes the CRAB criteria for myeloma-related organ damage: hypercalcemia, renal insufficiency, anemia, and bone lesions. Any of these in the presence of clonal plasma cells indicates symptomatic myeloma.
- M-Protein Detection: The lecture explains that SPEP is the primary screening test for M-protein. The tall, narrow spike in the gamma region indicates monoclonal protein production.
- Lytic Bone Lesions: The lecture notes that myeloma bone lesions are characteristically lytic "punched-out" lesions because plasma cells secrete factors that activate osteoclasts while suppressing osteoblasts. This is why bone scans are often negative.
- Cast Nephropathy: Renal failure in myeloma is often due to light chains binding to Tamm-Horsfall protein, forming obstructing tubular casts.
Treatment Plan
- Pre-treatment Evaluation:
- Echocardiogram (baseline for cardiotoxic agents)
- Consider fertility preservation discussion
- Induction Therapy:
- VRd regimen: Bortezomib (proteasome inhibitor) + Lenalidomide (IMiD) + Dexamethasone
- Consider adding daratumumab (anti-CD38) in high-risk patients
- 4-6 cycles
- Supportive Care:
- Bisphosphonates (zoledronic acid) for bone disease
- IV fluids and bisphosphonates for hypercalcemia
- VTE prophylaxis (IMiDs increase thrombosis risk)
- Pain management
- Transplant Evaluation:
- Autologous stem cell transplant candidacy assessment
- High-dose melphalan conditioning
- Maintenance:
- Lenalidomide maintenance post-transplant
Teaching Points
- CRAB criteria define symptomatic myeloma requiring treatment
- M-protein detected on SPEP; immunofixation confirms type
- Bone lesions are lytic (no osteoblastic activity) - bone scans are often negative
- VRd (bortezomib-lenalidomide-dexamethasone) is standard induction
- Autologous transplant improves survival in eligible patients